Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells

Figure 3

Enavatuzumab activated immune effector cells in responding tumor xenograft model. Splenocytes were isolated from tumor-bearing mice after enavatuzumab treatment and phenotyped by flow cytometry. (a) CD45⁺ cells were gated out from dead cells and other cell types. Of the live CD45⁺ cells, monocyte (CD11b^high) and NK-like (CD11b^low) cells were gated based on cell size and CD11b expression. (b, c) Splenocytes from SN12C or HCT116 tumor-bearing mice were assessed for DX5 and CD27 on monocyte-like cells (CD45⁺CD11b^high) and for DX5 on NK-like cells (CD45⁺CD11b^low) after enavatuzumab treatment. Enavatuzumab treatment significantly upregulated expression of both markers in SN12C tumor-bearing mice (, ).

(a)

(b)

(c)